Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triptorelin
Drug ID BADD_D02297
Description Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
Indications and Usage Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Marketing Status Prescription
ATC Code L02AE04
DrugBank ID DB06825
KEGG ID D06247
MeSH ID D017329
PubChem ID 25074470
TTD Drug ID D03QRS
NDC Product Code 71161-106; 24338-150
Synonyms Triptorelin Pamoate | Pamoate, Triptorelin | Triptorelin Embonate | Embonate, Triptorelin | CL-118532 | CL 118532 | CL118532 | Trelstar | Triptorelin | LHRH, Trp(6)- | GnRH, Trp(6)- | LHRH, Tryptophyl(6)- | D-Trp-6-LH-RH | 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig) | Wy-42462 | Wy 42462 | Wy42462 | AY-25650 | AY 25650 | AY25650 | Decapeptyl | Decapeptyl Trimestral | Trimestral, Decapeptyl | Decapeptyl LP | Decapeptyl Depot
Chemical Information
Molecular Formula C64H82N18O13
CAS Registry Number 57773-63-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32) NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7 )NC(=O)C8CCC(=O)N8
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gravitational oedema08.01.07.005; 02.05.04.014--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypokinesia17.01.02.009--Not Available
Hypotension24.06.03.002--
IIIrd nerve paralysis17.04.02.003; 06.05.02.011--Not Available
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Injection site erythema12.07.03.001; 08.02.03.001; 23.03.06.015--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Irritability08.01.03.011; 19.04.02.013--
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.004--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Libido decreased21.03.02.005; 19.08.03.001--
Local reaction08.01.03.012--Not Available
Loss of libido19.08.03.003--Not Available
Lymphocyte count increased13.01.06.007--
Lymphocytosis01.02.01.003--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages